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Cost-Effectiveness of HIV Treatment as Prevention  
in Serodiscordant Couples
To the Editor: We applaud the recent modeling 
study by Walensky et al. (Oct. 31 issue)1 as a com-
pelling argument that, in principle, human im-
munodeficiency virus (HIV) treatment as preven-
tion is cost-effective. However, the authors model 
only first- and second-order transmissions, 
thereby ignoring the dynamics of the full sexual 
network. Recent studies have shown that this 
modeling approach overestimates the effect of 
treatment as prevention, because many infec-
tions come from other parts of the network.2,3
Using the same assumptions regarding the 
effectiveness of antiretroviral therapy (ART) as 
Walensky et al., we reran our simulation model 
of the South African HIV epidemic, STDSIM, 
which includes detailed sexual-network dynam-
ics.3 We predict that, on a population level, treat-
ment as prevention for serodiscordant couples 
would prevent 12% of new infections in South 
Africa after 5 years, whereas treatment as pre-
vention for all HIV-infected people (90% coverage) 
would prevent 25% of new infections (Fig. 1). 
Both values are much lower than the 69% pre-
dicted by Walensky et al.
To maximize the effects of ART, policymakers 
require a comprehensive analysis of both treat-
ment and prevention benefits. This is where 
traditional cohort models for cost-effectiveness 
analyses, such as the Cost-Effectiveness of Pre-
venting AIDS Complications (CEPAC) model,1 fall 
short.
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The authors reply: There are several important 
differences between the CEPAC and STDSIM 
models, any one of which could account for our 
finding of more HIV cases prevented than in the 
analysis presented by Hontelez and de Vlas; two 
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Figure 1. Cumulative Proportion of HIV Infections 
Averted by Treatment as Prevention in South Africa 
over a 5-Year Period, as Predicted by the STDSIM Model.
According to this model, treatment as prevention for 
serodiscordant couples would prevent 12% of new 
infections in South Africa after 5 years, whereas treat-
ment as prevention for all HIV-infected people would 
prevent 25% of new infections. These values are much 
lower than the 69% reduction among serodiscordant 
couples that was predicted by Walensky et al.1
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are highlighted. First, we concentrate on serodis-
cordant couples in long-term partnerships (the 
target population of the HIV Prevention Trials 
Network 052 study); Hontelez and de Vlas simu-
late a generalized epidemic. Second, we focus on 
patients who are already identified and in care 
(treatment as prevention). In contrast, Hontelez 
and de Vlas describe an analysis of a test-and-
treat strategy in which a patient’s choice not to 
undergo HIV testing, an inadequate linkage to 
care, and a lack of initiation of ART would all 
attenuate the intervention effect.
We respectfully disagree with the suggestion 
that by restricting attention to first- and second-
order transmissions we failed to account for a 
substantial number of downstream infections. 
As noted in Table 2 of our article and in Figure 
S2 in the Supplementary Appendix (available with 
the full text of our article at NEJM.org), even 
second-order infections had no material effect 
on our findings over a period of 5 years. 
Projections beyond second-order infections in 
serodiscordant couples require assumptions about 
the future (e.g., ART efficacy, loss to follow-up, 
and sexual behavior) that are well beyond the 
trial data and unnecessary to reach our critical 
policy conclusions.
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Circulatory Shock
To the Editor: In their review of circulatory 
shock, Vincent and De Backer (Oct. 31 issue)1 re-
port that hypoperfusion can be apparent through 
the skin (cold extremities), the kidney (low uri-
nary output), and the brain (altered mental state). 
We believe that the liver should also be included 
in this list of key organs that are markers of 
shock. In cardiogenic shock, in which hypoper-
fusion is usually associated with increased cen-
tral venous pressure, hepatomegaly can be clin-
ically apparent by palpation, and abdominal 
discomfort due to stretching of the liver capsule 
may be a symptom. There is often an increase in 
levels of conjugated bilirubin, alkaline phos-
phatase, and aminotransferases that mimics 
the increase observed in cholelithiasis.2 Altera-
tion of coagulation can be present with an in-
crease in the international normalized ratio.3 
This cardio–hepatic interaction in shock gener-
ally results in the so-called hypoxic hepatitis or 
acute cardiogenic liver injury and has important 
prognostic implications.3,4 Can the authors com-
ment on hepatic dysfunction as an indicator of 
shock?
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To the Editor: In their initial assessment of 
shock states, the authors do not reference the 
obtaining of an electrocardiogram (ECG) in the 
algorithm presented. The ECG is critical in evalu-
ating a patient with circulatory shock and may 
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